What type of study is this?

This is a Quantitative Study study.

October 17, 2025Open Access

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia

View Full Paper

Ask AI

Bookmark

Dynamic BH3 profiling effectively predicts remission likelihood to chemotherapy in acute myeloid leukemia.
A fixed-drug panel was tested in myeloblasts from 92 AML patients, identifying unique interpatient responses.
Associations were found between drug-induced apoptotic priming and established AML clinical characteristics.
Dynamic BH3 profiling may enhance personalized treatment strategies by indicating sensitivity to specific drugs.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Prospectively assessed dynamic BH3 profiling in 92 AML patients demonstrates predictive value for treatment response, implying improved targeted therapy strategies.

Cite This Study

Minihane et al. (2025) studied this question.

synapsesocial.com/papers/68f199ccde32064e504dd30a https://doi.org/10.1101/2025.10.14.682414

View Full Paper

Ask AI

Bookmark

Implication

Prospectively assessed dynamic BH3 profiling in 92 AML patients demonstrates predictive value for treatment response, implying improved targeted therapy strategies.

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia

Key Points

Discussion

Implication

Cite This Study

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider